Acquired Company

PharmAthene completed its merger with Altimmune on 5/4/2017 and the combined company was renamed Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. Show more

910 Clopper Road, Gaithersburg, MD, 20878, United States

https://altimmune.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

566M

52 Wk Range

$2.90 - $7.73

Previous Close

$4.52

Open

$4.52

Volume

2,973,895

Day Range

$4.52 - $4.83

Enterprise Value

179.6M

Cash

210.8M

Avg Qtr Burn

-11.9M

Insider Ownership

0.72%

Institutional Own.

48.92%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Metabolic dysfunction-associated steatohepatitis (MASH)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Alcohol-Associated Liver Disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Alcohol Use Disorder (AUD)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Obesity	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NasoVAX Details Influenza	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HepTCell Details Chronic hepatitis B	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NasoShield (Vaccine) Details Anthrax, Bacterial infection	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
T-COVID Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AdCOVID Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.